- Home
- BORR vs MNKD Comparison
BORR vs MNKD Comparison
Compare BORR & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BORR | MNKD |
|---|---|---|
| Founded | 2016 | 1991 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2017 | 2004 |
Fundamental Metrics
Financial Performance| Metric | BORR | MNKD |
|---|---|---|
| Price | $6.12 | $3.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.25 | ★ $8.75 |
| AVG Volume (30 Days) | ★ 7.3M | 5.3M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 0.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $24.57 |
| Revenue Next Year | $12.39 | $14.12 |
| P/E Ratio | ★ $20.64 | $163.25 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $1.55 | $2.94 |
| 52 Week High | $6.18 | $6.51 |
Technical Indicators
Market Signals| Indicator | BORR | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 66.74 | 17.38 |
| Support Level | $2.66 | N/A |
| Resistance Level | N/A | $6.08 |
| Average True Range (ATR) | 0.33 | 0.39 |
| MACD | 0.00 | -0.30 |
| Stochastic Oscillator | 87.86 | 3.37 |
Price Performance
Historical ComparisonAbout BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.